Heidi Hittner
About Heidi Hittner
Heidi Hittner is Executive Vice President and Chief of Staff at agilon health (NYSE: AGL). She serves as a strategic partner and operational leader to the CEO, overseeing Centralized Operations (quality, risk adjustment, implementation, process excellence) as well as Marketing and Communications . She has been with agilon since the “class of 2019,” and was previously the company’s Chief Experience Officer . In July 2025, she was named to the Office of the Chairman established during the leadership transition following the CEO’s resignation .
Education: Master’s and BS in Physical Therapy, Loma Linda University .
Performance context: agilon’s 2024 annual incentive design emphasized profitability and operating execution (Adjusted EBITDA 55% weight; membership, experience/quality, team & culture; medical margin modifier), indicating the company’s near-term focus for leadership execution .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| agilon health | EVP & Chief of Staff (prior: Chief Experience Officer) | 2019–present (tenure noted as “class of 2019”) | Leads Centralized Ops (quality, risk adjustment, implementation, process excellence) and Marketing/Comms; prior CXO focused on medical quality improvement, cost management, and organic growth |
| Fresenius Medical Care North America | Senior leadership advancing value-based care strategies | Not disclosed | Led initiatives to advance value-based care strategies |
| Concentra | National operations leader; led NPS transformation | Not disclosed | Drove national operations and a successful Net Promoter Score transformation |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Ardmore Institute of Health | Board of Trustees | Not disclosed | External nonprofit board service |
Fixed Compensation
Note: Hittner is not listed among the Named Executive Officers (NEOs) in the 2025 Proxy (DEF 14A), and therefore her individual base salary and bonus were not disclosed in the Summary Compensation Table. The SCT covers CEO, CFO, and other NEOs only . The executive officers table in the proxy does not enumerate Hittner, further explaining the absence of her pay disclosure in that filing .
| Metric | 2024 (USD) | Disclosure status |
|---|---|---|
| Base salary | — | Not disclosed in 2025 DEF 14A; Hittner not an NEO in SCT coverage |
| Target bonus % | — | Not disclosed for Hittner; company NEO target was 75% of salary (context) |
| Actual annual bonus | — | Not disclosed for Hittner |
Performance Compensation
Company design (context for executive incentives; Hittner-specific targets not disclosed): for FY2024, agilon used the following metrics and weights for NEO annual incentives, plus a medical margin modifier. This framework indicates focus areas likely cascading into operating leaders’ objectives.
| Metric | Weight | Targeting/notes | Source |
|---|---|---|---|
| Adjusted EBITDA | 55% | Profitability emphasis | |
| Year-end membership – existing markets | 5% | Growth in existing markets | |
| New market membership growth | 10% | Expansion-driven growth | |
| Experience (Gaps Closed, PCP touchpoints) | 10% (aggregate) | Patient and PCP engagement | |
| Quality (chronic condition reassessment rates) | 10% | Clinical quality measure | |
| Team & culture | 10% | Human capital | |
| Medical margin modifier | ±15% | Adjusts payout up/down |
Additional context: In 2024 the committee recognized retention risks and used discretion to pay most NEOs 50% of target despite a formula outcome of 28.7%, while the CEO received 28.7% aligned to company results .
Equity Ownership & Alignment
| Policy/Item | agilon health terms | Hittner-specific status |
|---|---|---|
| Stock ownership guidelines | CEO: 6x salary; all other executive officers: 2x salary; must hold 100% of net shares from awards until compliant | Not disclosed whether Hittner is formally designated an “executive officer” under the policy or her compliance status |
| Hedging/pledging | Hedging and pledging of AGL securities prohibited for employees, officers, directors | No pledging/hedging indicated for Hittner; policy prohibits |
| Clawback policy | SEC/NYSE-compliant 3-year recoupment for incentive comp on restatement; recover excess over restated results | Applies to executive officers; individual recoveries not disclosed |
| Beneficial ownership | Proxy table covers >5% holders, directors, and NEOs (not all executives) | No individual line for Hittner (not a director or NEO); ownership not disclosed |
Outstanding awards and vesting: Not disclosed for Hittner. The proxy includes “Outstanding Equity Awards” only for NEOs (e.g., CEO/CFO/CMO/CTO), not Hittner .
Employment Terms
- Employment agreement, severance, change-in-control: The proxy details contracts for certain NEOs (CEO, CFO, others) including salary, target bonus, sign-on equity, severance multiples and vesting mechanics; no separate employment agreement or severance terms are disclosed for Hittner in the DEF 14A .
- Leadership transition in 2025: The July 29, 2025 establishment of the Office of the Chairman (including Hittner) did not disclose any changes to her compensation; the 8‑K noted interim principal executive officer designations for CFO and Chief Markets Officer but did not specify compensation changes for other members .
Performance & Track Record
- Operating mandate: As EVP & Chief of Staff, Hittner oversees quality, risk adjustment, implementation, process excellence, and Marketing/Comms—capabilities central to agilon’s profitability drivers (Adjusted EBITDA and medical margin) referenced in the 2024 plan .
- Tenure: With agilon since the 2019 cohort; previously held senior roles at Fresenius Medical Care North America and Concentra, where she led an NPS transformation—experience aligned with improving quality and patient/PCP experience metrics used in company incentive design .
- 2025 transition: Hittner was named to the Office of the Chairman following the CEO’s resignation; the company withdrew FY2025 guidance simultaneously, signaling heightened operational focus during the transition .
Risk Indicators & Red Flags
- Securities litigation: In re agilon health, inc. Securities Litigation (W.D. Tex.) lists Hittner among defendants in filings; the case includes motions to dismiss and scheduling entries through 2025. This reflects litigation overhang but is not an admission of wrongdoing .
- Governance and pay practices: Hedging/pledging prohibited; SEC/NYSE-compliant clawback policy adopted—mitigates certain alignment risks .
- Say-on-Pay support: 93.4% approval at the 2024 annual meeting for NEO pay, indicating historically strong investor support for program design; note this relates to NEOs, not Hittner individually .
Say-on-Pay & Shareholder Feedback
| Year/Meeting | Say-on-Pay approval | Notes |
|---|---|---|
| 2024 Annual Meeting | 93.4% of votes cast approved NEO compensation | Committee kept 2024 program largely consistent with 2023, with modifications to emphasize profitability |
Expertise & Qualifications
- Degrees: Master’s and BS, Physical Therapy, Loma Linda University .
- Domain expertise: Value-based care operations, risk adjustment, quality, patient experience, large-scale operations/NPS programs; prior leadership at Fresenius and Concentra .
- Internal stature: Member of Office of the Chairman as of July 29, 2025 .
Equity Sales/Insider Trading Activity
- Form 4s: No Form 4 filings naming Hittner were identified in our search; individual insider transaction history is not disclosed in the 2025 proxy. Consider targeted EDGAR owner-name search for updates .
- Policy constraints: Hedging and pledging prohibited; ownership guidelines apply to executive officers, which reduces potential misalignment from leverage/hedging .
Investment Implications
- Alignment: While Hittner’s individual pay elements are not publicly disclosed, agilon’s incentive architecture (Adjusted EBITDA, medical margin modifier, membership, quality/experience) aligns executive focus with profitability and operating execution—areas directly under her scope (risk adjustment, quality, process excellence) .
- Execution lever: Placement in the Office of the Chairman during the 2025 leadership transition indicates elevated responsibility and potential influence on near-term operating outcomes critical to sentiment and valuation (e.g., RAF accuracy, medical margin predictability) .
- Risk: Ongoing securities litigation naming Hittner contributes to headline risk, though outcomes and merits remain uncertain; balance against governance mitigants (clawback, no hedging/pledging) and historically strong Say‑on‑Pay support for program design .
- Data gaps: Lack of disclosed individual compensation, ownership, and vesting schedules for Hittner limits direct analysis of selling pressure or retention economics; monitor future 8‑Ks/DEF 14A and EDGAR for any appointment/status changes that could trigger Item 402 disclosure .
Key monitoring: (1) Any new disclosure that elevates Hittner to NEO status (would disclose salary/bonus/equity), (2) Form 4 filings, (3) updates on RAF/medical margin execution in earnings, (4) litigation milestones and any related governance or compensation responses .